Pale Fire Capital SE’s Tarsus Pharmaceuticals TARS Stock Holding History

Pale Fire Capital SE’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$617K	Buy	9,802 +4,150	+73%	+$265K	0.04%	40
2026 Q1	$396K	Buy	5,652 +3,200	+131%	+$224K	0.03%	39
2025 Q4	$201K	Sell	2,452 -4,623	-65%	-$345K	0.01%	50
2025 Q3	$420K	Buy	+7,075	New	+$348K	0.05%	38

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pale Fire Capital SE's TARS Position: Q2 2026 in Review

Pale Fire Capital SE increased its Tarsus Pharmaceuticals (TARS) stake by 73% in Q2 2026, buying an estimated $265K and bringing the position to 9,802 shares worth $617K. The position accounts for 0.04% of the portfolio, ranked #40.

Pale Fire Capital SE first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Pale Fire Capital SE held 9,802 shares of Tarsus Pharmaceuticals worth $617K as of Q2 2026.
Pale Fire Capital SE bought 4,150 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $265K.
Tarsus Pharmaceuticals made up 0.04% of Pale Fire Capital SE's portfolio in Q2 2026, its #40 holding.
Pale Fire Capital SE first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.